EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment

Xiaohong Pu, Lin Li, Feng Xu, Ziyu Wang, Yao Fu, Hongyan Wu, Jun Ren, Jun Chen, Beicheng Sun

Journal of Cancer Research and Clinical Oncology · 28.08.2024 · 150 (8)

DOI: 10.1007/s00432-024-05894-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 28.08.2024. Verfasst von Xiaohong Pu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, Jian…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Tumor Microenvironment, Bile Duct Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Social Science Fund of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to establish a uniform standard for the interpretation of HER2 gene and protein statuses in intrahepatic cholangiocarcinoma (ICC). We also intended to explore the clinical pathological characteristics, molecular features, RNA expression and immune microenvironment of HER2-positive ICC.

Methods

We analyzed a cohort of 304 ICCs using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to identify HER2 status. Comprehensive analyses of the clinicopathological, molecular genetic, and RNA expression characterizations of ICCs with varying HER2 statuses were performed using next-generation sequencing. We further investigated the tumor microenvironment of ICCs with different HER2 statuses using IHC and multiplex immunofluorescence staining.

Results

HER2/CEP17 ratio of ≥ 2.0 and HER2 copy number ≥ 4.0; or HER2 copy number ≥ 6.0 were setup as FISH positive criteria. Based on this criterion, 13 (4.27%, 13/304) samples were classified as having HER2 amplification. The agreement between FISH and IHC results in ICC was poor. HER2-amplified cases demonstrated a higher tumor mutational burden compared to non-amplified cases. No significant differences were observed in immune markers between the two groups. However, an increased density of CD8 + CTLA4 + and CD8 + FOXP3 + cells was identified in HER2 gene-amplified cases.

Conclusion

FISH proves to be more appropriate as the gold standard for HER2 evaluation in ICC. HER2 gene-amplified ICCs exhibit poorer prognosis, higher mutational burden, and T cell exhaustion and immune suppressed microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaTumor MicroenvironmentBile Duct NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationGene AmplificationHumansFemaleMiddle AgedMaleAgedIn Situ Hybridization, FluorescenceAdultBiomarkers, TumorT-LymphocytesPrognosisT-Cell Exhaustion

Stichwörter der Autor:innen

HER2 statusImmunohistochemistryIn fluorescence in situ hybridizationIntrahepatic cholangiocarcinomaT cell infiltration

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, Jiangsu Province, China.
  • Department of Medical Imaging, The Affiliated Suqian First People's Hospital of Nanjing Medical University, 223800, Suqian, Jiangsu Province, China.
  • Department of General Surgery, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou, 225000, Jiangsu Province, China. freezingfall@163.com.
  • Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, Jiangsu Province, China. ichenjun@qq.com.
  • Medical School, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, Jiangsu Province, China. Sunbc@nju.edu.cn.

Förderung

  • National Social Science Fund of China

Zitieren

APA

Pu, X., Li, L., Xu, F., Wang, Z., Fu, Y., Wu, H., Ren, J., Chen, J., & Sun, B. (2024). HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment. Journal of Cancer Research and Clinical Oncology, 150(8). https://doi.org/10.1007/s00432-024-05894-0

Vancouver

Pu X, Li L, Xu F, Wang Z, Fu Y, Wu H, et al. HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment. Journal of Cancer Research and Clinical Oncology. 2024;150(8). doi:10.1007/s00432-024-05894-0

BibTeX
@article{Pu2024,
  author = {Pu, Xiaohong and Li, Lin and Xu, Feng and Wang, Ziyu and Fu, Yao and Wu, Hongyan and Ren, Jun and Chen, Jun and Sun, Beicheng},
  title = {HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {8},
  doi = {10.1007/s00432-024-05894-0}
}
Kostenlos starten →